Immune-modulatory effects of bortezomib in GVHD.
Zweegman
S
S
Janssen
J J W M
JJ
Lokhorst
H M
HM
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000378:metabolism; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D016207:Cytokines / Q000378:metabolism; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D007249:Inflammation; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D016328:NF-kappa B / Q000378:metabolism; D010954:Plasmacytoma / Q000188:drug therapy; D011719:Pyrazines / Q000627:therapeutic use*; D013154:Spleen / Q000166:cytology / Q000378:metabolism; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000378:metabolism; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D001897:Boronic Acids; D016207:Cytokines; D016328:NF-kappa B; D011719:Pyrazines; D000069286:Bortezomib